ET-receptor antagonism, myocardial gene expression, and ventricular remodeling during CHF in rats

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 275, Issue 3 44-3, 1998, Pages

  Øie, Erik ^a   Bjønerheim, Reidar ^a   Grøgaard, Haakon K ^a   Kongshaug, Heidi ^a   Smiseth, Otto A ^a   Attramadal, Håvard ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Endothelin; Hypertrophy; Ischemic heart failure

Indexed keywords

ENDOTHELIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONGESTIVE HEART FAILURE; ECHOCARDIOGRAPHY; GENE EXPRESSION REGULATION; HEART STRESS; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE HYPERTROPHY; NONHUMAN; PATHOPHYSIOLOGY; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY;

EID: 33750850805     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.1998.275.3.h868     Document Type: Article

References (19)

1. Arai, M., A. Yoguchi, T. Iso, T. Takahashi, S. Imai, K. Murata, and T. Suzuki. Endothelin-1 and its binding sites are upregulated in pressure overload cardiac hypertrophy. Am. J. Physiol, 268 (Heart Circ. Physiol. 37): H2084-H2091, 1995.
2. Cavero, P. G., W. L. Miller, D. M. Heublein, L. L. Aarhus, and J. C. Burnett, Jr. Endothelin in experimental congestive heart failure in the anesthetized dog. Am. J. Physiol. 259 (Renal Fluid Electrolyte Physiol. 28): F312-F317, 1990.
3. Clozel, M., V. Breu, G. A. Gray, B. Kalina, B. M. Loffler, K. Burri, J. M. Cassal, G. Hirth, M. Muller, W. Neidhart, and H. Ramuz. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 270: 228-235, 1994.
4. Cody, R. J., G. J. Haas, P. F. Binkley, Q. Capers, and R. Kelley. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85: 504-509, 1992.
5. Creminon, C., Y. Frobert, A. Habib, J. Maclouf, C. Patrono, P. Pradelles, and J. Grassi. Enzyme immunometric assay for endothelin using tandem monoclonal antibodies. J. Immunol. Methods 162: 179-192, 1993.
6. D'Orleans-Juste, P., A. Claing, T. D. Warner, M. Yano, and S. Telemaque. Characterization of receptors for endothelins in the perfused arterial and venous mesenteric vasculatures of the rat. Br. J. Pharmacol. 110: 687-692, 1993.
7. Fraccarollo, D., K. Hu, P. Galuppo, P. Gaudron, and G. Ertl. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation 96: 3963-3973, 1997.
8. Ihara, M., T. Fukuroda, T. Saeki, M. Nishikibe, K. Kojiri, H. Suda, and M. Yano. An endothelin receptor (ETA) antagonist isolated from Streptomyces misakiensis. Biochem. Biophys. Res. Commun. 178: 132-137, 1991.
9. B receptor antagonist. Circulation 93: 2068-2079, 1996.
10. Kajstura, J., W. Cheng, K. Reiss, W. A. Clark, E. H. Sonnenblick, S. Krajewski, J. C. Reed, G. Olivetti, and P. Anversa. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab. Invest. 74: 86-107, 1996.
11. Kasai, H., M. Takanashi, C. Takasaki, and M. Endoh. Pharmacological properties of endothelin receptor subtypes mediating positive inotropic effects in rabbit heart. Am. J. Physiol. 266 (Heart Circ. Physiol. 35): H2220-H2228, 1994.
12. Kiowski, W., G. Sutsch, P. Hunziker, P. Muller, J. Kim, E. Oechslin, R. Schmitt, R. Jones, and O. Bertel. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 346: 732-736, 1995.
13. Li, J. S., and E. L. Schiffrin. Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension 25: 495-500, 1995.
14. Masaki, T. Possible role of endothelin in endothelial regulation of vascular tone. Annu. Rev. Pharmacol. Toxicol. 35: 235-255, 1995.
15. Moravec, C. S., E. E. Reynolds, R. W. Stewart, and M. Bond. Endothelin is a positive inotropic agent in human and rat heart in vitro. Biochem. Biophys. Res. Commun. 159: 14-18, 1989.
16. Mulder, P., V. Richard, G. Derumeaux, M. Hogie, J. P. Henry, F. Lallemand, P. Compagnon, B. Macè, E. Comoy, B. Letac, and C. Thuillez. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 96: 1976-1982, 1997.
17. B receptors in the hypertrophic effects of ET-1 in rabbit ventricular cardiomyocytes. J. Cardiovasc. Pharmacol. 29: 350-359, 1997.
18. 17a. Øie, E., L. E. Vinge, T. Tønnessen, H. K. Grøgaard, H. Kjekshus, G. Christensen, O. A. Smiseth, and H. Attramadal. Transient, isopeptide-specific induction of myocardial endothelin-1 mRNA during congestive heart failure in rats. Am. J. Physiol. 273 (Heart Circ. Physiol. 42): H1727-H1736, 1997.
19. Omland, T., R. T. Lie, A. Aakvaag, T. Aarsland, and K. Dickstein. Plasma endothelin as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 89: 1573-1579, 1994.